Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the U.S. Food and Drug Administration ...
At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...
Patients with tenosynovial giant cell tumor can take some comfort in knowing that this rare type of tumor affecting joints won’t kill them. But that doesn’t make living with the disease easy. Merck ...
MSK orthopedic surgeon Dr. Jonathan Forsberg examines Michelle Smith-Levitin’s leg at a follow-up appointment — a first-of-its-kind surgical implant saved her leg. The tennis court was Michelle ...
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback